Zolbetuximab is under clinical development by Astellas Pharma and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III drugs for Gastric Cancer have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Zolbetuximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zolbetuximab (claudiximab, IMAB-362) is under development for the treatment of advanced adenocarcinoma of the Gastroesophageal Junction, gastric cancer and metastatic pancreatic adenocarcinoma. The drug candidate is administered as an intravenous infusion. It is an Ig1 iMAB acts by targeting splice variant of claudin 18 target (claudin 18.2). It is developed based on ideal monoclonal antibody (IMABS) therapeutics. It was under development for the treatment of solid tumors including ovarian cancer and lung cancer.
Astellas Pharma overview
Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.
For a complete picture of Zolbetuximab’s drug-specific PTSR and LoA scores, buy the report here.